Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 40 Show results per page	View Search Criteria \| Help With Results


1.		Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutent

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology, Treatment				Enrolling by invitation				Not specified				Pharmaceutical / Industry				A6181146 NCT00444795

Last Modified: 4/7/2005 First Published: 5/28/2004


2.		Phase III Randomized Study of SU011248 in Patients With Imatinib Mesylate-Resistant or -Intolerant Malignant Gastrointestinal Stromal Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-04028 PFIZER-A6181004, UCLA-0311021-01, NCT00085618


3.		TroVax Renal Immunotherapy Survival Trial

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				TV3/001/06 NCT00397345


4.		Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				A6181038 NCT00113529


5.		SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				Other				05-439 NCT00361244


6.		Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				NN028-1642 EudraCT No: 2006-005751-16, NCT00617253

Last Modified: 10/25/2007 First Published: 4/23/2004


7.		Phase II Study of SU011248 in Patients With Metastatic Colorectal Adenocarcinoma Who Failed Prior Treatment With Irinotecan, Oxaliplatin, and a Fluoropyrimidine With or Without Bevacizumab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-03143 PFIZER-A6181003, PFIZER-PHA-RTKC-0511, NCT00082771


8.		Treatment With SU11248 in Patients With Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				RTKC-0511-015 NCT00056693


9.		SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				A6181039 NCT00089648

Last Modified: 5/4/2005 First Published: 10/25/2004


10.		Phase II Study of SU011248 in Women With Anthracycline- or Taxane-Resistant Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0402087-01 PFIZER-A6181002, PFIZER-PHA-RTKC-0511, NCT00095615

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute